Category: Diseases 2.0

Clinical Correlations


Alzheimer’s Disease 2.0: State of Diagnosis

Alzheimer's_disease_brain_comparisonBy Karen McCloskey, MD

Peer Reviewed

In May 2012, The U.S. Department of Health and Human Services unveiled the “National Plan to Address Alzheimer’s Disease,” in response to legislation signed by President Obama in January, 2011 establishing the National Alzheimer’s Project Act. …

Read More

Optimism

Glass-of-waterBy Adam Blaisdell

Peer Reviewed

Present Day – The patient is a 61 year-old male who presents with a one-week history of jaundice and intense pruritus. He has a medical history significant for hepatitis C virus (HCV) infection (genotype 1a) diagnosed 15 years ago, which was never treated.…

Read More

Measles in 2016

Measles_in_African_Child_3By Chio Yokose, MD

Peer Reviewed

On March 13, 2013, a young traveler returned home from London to our neighboring borough of Brooklyn, NY. Among this individual’s possessions was an active measles infection, one which subsequently led to one of the largest outbreaks of measles in the United States since 1996 [1]. …

Read More

Shifting Paradigms in Cancer: Vaccines

Joshua Horton

Peer Reviewed

We are not winning the war against cancer, if war is even an appropriate metaphor. When Richard Nixon signed the National Cancer Act into effect in 1971, many predicted that cancer would be a thing of the past within 5 years.…

Read More

The Rise in Tick-Borne Diseases: Is Climate Change Responsible?

By Nadia Jafar

Peer Reviewed

As a resident of Connecticut, I grew up acutely aware of tick-borne diseases. Nonetheless, I was surprised to see at least 3 cases of tick-borne infections during the month of my Medicine clerkship. This drove me to research the incidence of tick-borne diseases, specifically in the US, and the possible factors contributing to their increased prevalence.…

Read More

Gay Men, Barebacking and the New Little Blue Pill: The awkward interface of medicine and gay sex.

By Richard E. Greene, MD

Peer Reviewed

In July of 2012, the FDA approved the use of Tenofovir-Emtricitabine (Truvada, a single blue pill) daily as Pre-Exposure Prophylaxis (PrEP) in men with persistent risk for contracting HIV infection. The idea of PrEP has ignited a firestorm of concern among healthcare providers about how, when and in whom to use PrEP, if at all.…

Read More